ABCG2 and breast carcinoma: BCRP overexpression in breast cancer is associated with resistance to mitoxantrone (which is considered to be its prototypical substrate) and to topotecan, 7-ethyl-10-hydroxycamptothecin, anthracycline, and tamoxifen [174].